Brief: Intercept Pharmaceuticals, Unit Enters Into Settlement With Lupin Ltd, Lupin Pharmaceuticals

Intercept Pharmaceuticals

21/02/2023 13:33

Feb 21 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT PHARMACEUTICALS INC-ON FEB 20, CO AND UNIT
ENTERED
INTO SETTLEMENT WITH LUPIN LIMITED AND LUPIN PHARMACEUTICALS,
INC.
    * INTERCEPT PHARMACEUTICALS-AGREEMENT RESOLVES LITIGATION
CONCERNING SUBMISSION BY LUPIN OF ANDA FOR GENERIC VERSION OF
OCALIVA
    * INTERCEPT- GAVE LUPIN NON-EXCLUSIVE, NON-SUBLICENSABLE,
NON-TRANSFERABLE, ROYALTY-FREE LICENSE TO COMMERCIALIZE GENERIC
VERSION OF OCALIVA IN U.S.
    * INTERCEPT PHARMACEUTICALS- LICENSE TO COMMERCIALIZE ITS
GENERIC
VERSION OF OCALIVA IN UNITED STATES COMMENCING ON FEB 28, 2034

Further company coverage:  ICPT.O 
 ((Reuters.Briefs@thomsonreuters.com;))